The keys to successful CDMO collaboration during development
When drug development companies prepare to enter the clinical phase, they must produce both the Drug Substance (API) and the Drug Product (IMP). Since many organizations lack the in-house capabilities for this, they often turn to Contract Development and Manufacturing Organizations (CDMOs) to handle the production.
Join this full-day to discover how to identify, evaluate, and select the right partner for your needs. Learn from industry experts with hands‑on experience in CDMO collaborations and gain insights, proven strategies, and best practices.
Confirmed Speakers
- Mikael Moge, BioArctic
- Carina Siversson, Galenica
- Agneta Larhed, RegSmart
- Ann-Christin Malmborg Häger, Hager Consulting
- Tuulikki Lindmark, TuuLifeScience
- Nelly Fransén, Arex Advisor
- Sylvie Ryckebusch, BioInvent International
In cooperation with Sweden Drug Delivery Industry Group and Medicon Village.